Oritani K, Medina K L, Tomiyama Y, Ishikawa J, Okajima Y, Ogawa M, Yokota T, Aoyama K, Takahashi I, Kincade P W, Matsuzawa Y
Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita City, Osaka 565-0871, Japan.
Nat Med. 2000 Jun;6(6):659-66. doi: 10.1038/76233.
We have identified an interferon-like cytokine, limitin, on the basis of its ability to arrest the growth of or kill lympho-hematopoietic cells. Limitin strongly inhibited B lymphopoiesis in vitro and in vivo but had little influence on either myelopoiesis or erythropoiesis. Because limitin uses the interferon alpha/beta receptors and induces interferon regulatory factor-1, it may represent a previously unknown type I interferon prototype. However, preferential B-lineage growth inhibition and activation of Janus kinase 2 in a myelomonocytic leukemia line have not been described for previously known interferons.
我们基于其阻止淋巴造血细胞生长或杀伤淋巴造血细胞的能力，鉴定出一种类干扰素细胞因子——限制素。限制素在体外和体内均强烈抑制B淋巴细胞生成，但对髓细胞生成或红细胞生成影响甚微。由于限制素利用干扰素α/β受体并诱导干扰素调节因子-1，它可能代表一种此前未知的I型干扰素原型。然而，此前已知的干扰素尚未有过在髓单核细胞白血病系中优先抑制B系生长和激活Janus激酶2的相关描述。
